Prostate cancer begins as an androgen-dependent tumor that undergoes clinical regression in response to pharmacological or surgical strategies that reduce testosterone concentration. Despite this ...
Daniel George, MD, Director of Genitourinary Oncology at Duke Cancer Institute and investigator for the CAPItello-281 trial, said: “Patients with PTEN-deficient metastatic hormone-sensitive prostate ...
Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer ...
The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
In 3 clinical trials investigating the use of androgen receptor pathway inhibitors (ARPIs) in nonmetastatic castration-resistant prostate cancer (nmCRPC), the primary endpoint of metastases-free ...
Sex differences are widespread across human development, physiological processes, and diseases, making it important to characterize the impact of sex differences in these areas. Understanding the ...
Sex differences are widespread across human development, physiological processes, and diseases, making it important to characterize the impact of sex differences in these areas. Understanding the ...
Morning Overview on MSN
Low testosterone in older men was tied to a leading cause of vision loss
Older men whose testosterone levels drop or are medically suppressed face a measurably higher risk of age-related macular ...
This report is the first to examine the influence of inherited variation in the androgen metabolic pathway on the efficacy of ADT, establishing the importance of pharmacogenomics on individual's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results